

1 **Scale Bar of Aging Trajectories for Screening Personal Rejuvenation Treatments**

2

3 Xilin Shen^{1,3,5,#}, Bingbing Wu^{1,3,6,#}, Wei Jiang^{1,3}, Yu Li^{1,3,4}, Yuping Zhang⁷, Kun Zhao^{1,3},
4 Nanfang Nie^{1,3,4}, Lin Gong^{1,3}, Yixiao Liu^{1,3}, Xiaohui Zou^{1,3,4}, Jian Liu^{3,8}, Jingfen Jin^{7*},
5 HongWei Ouyang^{1,2,3*}

6

7 ¹Dr. Li Dak Sum & Yip Yio Chin Center for Stem Cells and Regenerative Medicine,
8 and Department of Orthopedic Surgery of the Second Affiliated Hospital, Zhejiang
9 University School of Medicine, Hangzhou, Zhejiang 310003, PR China

10 ²Department of Sports Medicine, Zhejiang University School of Medicine, Hangzhou,
11 China.

12 ³Zhejiang University-University of Edinburgh Institute, Zhejiang University School of
13 Medicine, and Key Laboratory of Tissue Engineering and Regenerative Medicine of
14 Zhejiang Province, Zhejiang University School of Medicine, Hangzhou, Zhejiang
15 310058, PR China

16 ⁴Clinical Research Center, the First Affiliated Hospital, School of Medicine, Zhejiang
17 University

18 ⁵ College of Computer Science and Technology, Zhejiang University, Hangzhou,
19 310027, PR China

20 ⁶ International Institutes of Medicine, The 4th Affiliated Hospital of Zhejiang
21 University School of Medicine, Yiwu, Zhejiang, China

22 ⁷Nursing Department of The Second Affiliated Hospital of Zhejiang University School
23 of Medicine

24 ⁸ Department of Respiratory and Critical Care Medicine, the Second Affiliated Hospital,
25 Zhejiang University School of Medicine, Zhejiang University, Hangzhou 310009,
26 China

27 #Co-first author, *Corresponding author

28 Correspondence and requests for materials should be addressed to H.W.O.Y (Email:
29 hwoy@zju.edu.cn)

30 Corresponding address: 866 Yu Hang Tang Road, Hangzhou, Zhejiang, P.R. China,

31 310058, Fax/Phone: +086-0571-88208262

32

33 **Abstract:**

34 Although aging is an increasingly severe healthy, economic, and social global problem,
35 it is far from well-modeling aging due to the aging process's complexity. To promote
36 the aging modeling, here we did the quantitative measurement based on aging blood
37 transcriptome. Specifically, the aging blood transcriptome landscape was constructed
38 through ensemble modeling in a cohort of 505 people, and 1138 age-related genes were
39 identified. To assess the aging rate in the linear dimension of aging, we constructed a
40 simplified linear aging clock, which distinguished fast-aging and slow-aging
41 populations and showed the differences in the composition of immune cells. Meanwhile,
42 the non-linear dimension of aging revealed the transcriptome fluctuations with a crest
43 around the age of 40 and showed that this crest came earlier and was more vigorous in
44 the fast-aging population. Moreover, the aging clock was applied to evaluate the
45 rejuvenation effect of molecules *in vitro*, such as Nicotinamide Mononucleotide (NMN)
46 and Metformin. In sum, this study developed a *de novo* aging clock to evaluate age-
47 dependent precise medicine by revealing its fluctuation nature based on
48 comprehensively mining the aging blood transcriptome, promoting the development of
49 personal aging monitoring and anti-aging therapies.

50 **Key words:**

51 Aging; Transcriptome; Aging clock; Rejuvenation;

52

53

54

55

56

57

58

59

60

61

62

63 **Introduction:**

64 Life expectancy has increased dramatically in the past 150 years. It is expected
65 that the 1.5 billion people aged 65 years or over worldwide will outnumber adolescents
66 and youth aged 15 to 24 years (1.3 billion) in 2050¹. People aged 65 years and older are
67 experiencing the aging process, characterized by progressive impairment and loss of
68 physiological integrity and function, leading to an increased vulnerability to death².
69 Therefore, the world is facing an aging challenge.

70 Aging, a complex biological process, is far from well modeled though significant
71 efforts have been put into understanding the aging process and revealing patterns in
72 immune-aging³ and inflammatory-aging⁴ perspectives. Until now, ‘Omics’ technologies
73 (*e.g.*, genomics, metabolomics, metagenomics, proteomics, and transcriptomics) have
74 been widely applied to investigate and model the aging process⁵. Among these Omics,
75 transcriptomics by RNA sequencing is a mature and relatively low-cost omics
76 technology and has already been in clinical use. In addition, transcriptome-based aging
77 clocks, including the analyses of peripheral blood mononuclear cells (PBMCs)⁶,
78 muscle⁷, and dermal fibroblast⁸, are high in interpretability without compromising
79 accuracy⁹ compared with other aging clocks. However, most studies modeled aging as
80 a static linear process⁶⁻⁸, failure to model it as a dynamic process¹⁰. Given that recent
81 studies have shown the diversified early aging signs or pace¹¹ at middle age and the
82 fluctuation in plasma protein level¹⁰, examining the transcriptome changes of blood
83 samples in midlife can help investigate and model the aging process.

84 In the search for anti-aging intervention and drugs, a quantitative measurement of
85 sample biological age before and after intervention cannot be achieved without accurate
86 modeling. However, the lack of accuracy prevented their scientific and clinical usage
87 of the aging clocks. Of note, the application of transcriptome-based aging clock in drug
88 anti-aging effect assessment is still absent, leaving a gap between model construction
89 and application. Therefore, an accurate and applicable transcriptome-based aging clock
90 is required. This study aims to construct the aging trajectories using blood

91 transcriptomics and successfully developed a new aging clock capable of reflexing the
92 linear and dynamic changes with high accuracy using ensemble modeling. Moreover,
93 we investigated the possibility of using the new aging clock to screen rejuvenation
94 treatments.

95

96 **Results:**

97 **1. Trajectories of Aging Gene Expression Form Functional Modules.**

98 To dissect the transcriptome landscape of the aging process, we did the HiseqX
99 sequencing on blood samples from a cohort of 505 volunteers, including 208 male and
100 297 female participants with the age range from 18 to 68, with a median of 36 (Fig. S1-
101 A). First, we grouped genes with similar trajectories by unsupervised hierarchical
102 clustering to identify the changing pattern of age-related genes. Eight modules were
103 identified, of which five (Clusters 1-5) showed an upward trend, and Clusters 6-8 had
104 downward patterns (Fig. 1-A, B). As visualized in trajectory bundles (Fig. 1-B), some
105 patterns were generally linear, but others were non-linear. In some of the modules
106 (Clusters 5-8), gene expressions changed steadily, while other trajectories indicated
107 dramatic changes in a specific age range. Gene Ontology (GO) Enrichment analysis
108 was then conducted to infer its related biological function. The dot plot showed top
109 enriched GO terms in each module (Fig. 1-C, Supplement table 1). The first module
110 expression was enhanced at the age of 25-35, and its genes are related to ubiquitin
111 activity and immune cell proliferation. The second module was wave-like, and the
112 related genes in this module regulate transcription factor complex and interleukin-8
113 secretion. The age of 45 is the boosting point for the third module expression, of whose
114 genes were associated with mitochondria activity. The expression of the fourth and fifth
115 modules, including the genes enriched in neutrophil immune activity, was increased at
116 the age of 35-45. The other three modules (Clusters 6-8) with downward trends were
117 mainly involved in translation, including that the top terms were protein targeting to
118 membrane, RNA helicase activity, and viral translation, respectively. These biological
119 processes, enriched in these modules, correspond to previous studies of ubiquitin¹²,
120 immune cell¹³, mitochondria¹⁴, ribosome¹⁵ in aging. In sum, we mapped the trajectories

121 of the expression pattern of aging-related gene expression.

122

123 **2. Identification of Linear Age-Related Genes (ARGs).**

124 Linear fitting was first applied to identify Linear ARGs. As females have a longer
125 lifespan than man¹⁶, we applied the linear fitting for each gene with age and gender as
126 variables. 1,138 genes significantly affected by age were identified as Linear ARGs (t-
127 test for age effect: p-value < 0.05). Five hundred thirty genes were downregulated, and
128 608 were upregulated considering the age effect (Supplement table 2). *FMNL1* and
129 *NELL2* belong to the top five Linear ARGs (Fig. 2-A). Consistent with the previous
130 findings, *FMNL1* was reported increased in arterial endothelial aging¹⁷, and *NELL2* was
131 found to be downregulated in the elderly¹³. 1,221 (81.5%) of all previously summarized
132 ARGs in a meta-analysis⁶ were identified here, including 184 (15.1%) Linear ARGs.
133 94% of these Linear ARGs were associated with chronological age in the same
134 direction (Figure S2-A).

135 Moreover, Metascape¹⁸ enrichment analyses were performed on Linear ARGs of
136 both directions, respectively. The top enriched terms for upregulated Linear ARGs were
137 platelet activation, signaling and aggregation, regulated exocytosis, and apoptotic
138 signaling pathway. Those downregulated Linear ARGs were Eukaryotic translation
139 elongation, TNF-alpha/NF-kappa B signaling complex, and positive regulation of the
140 catabolic process (Fig. 2-B, Supplement table 3). Of note, the downregulated Linear
141 ARGs, including ribosome genes (*e.g.*, 25 RPS-genes and 37 RPL-genes (pseudogene
142 included)), are highly related to the biological processes in translation, similar to the
143 previous results⁶. Among the top Linear ARGs, *RPL5*, *RPL11*, and *RPL23A* were
144 reported as participants of ribosome biogenesis stress followed by the p53 activation¹⁹.

145 Furthermore, the percentage of variance explained by sex and age for each gene
146 was computed (Figure S2-B, C). It showed that the age-related genes were also
147 significantly related to sex, such as *RPS4Y1*, encoding a thioredoxin-binding protein,
148 apart from genes encoded by the Y chromosome. Taken together, we identified ARGs
149 by applying linear fitting and Metascape enrichment analyses.

150

151 **3. Ensemble Model as Aging Clock Was Constructed by Auto Machine** 152 **Learning Framework.**

153 To predict the biological age, we constructed an aging clock based on Linear
154 ARGs. The auto machine-learning technique was AutoGluon²⁰ by applying
155 hyperparameter search, model selection, and ensemble model construction (See
156 Method). The cohort was first divided as train set and test set with a ratio of 3:1. Then,
157 the train set was further divided, 80% of which was used for model construction and
158 20% for validation. Finally, the top models were trained and tested in mean absolute
159 error (MAE) (Fig. 2-C, D), and the weighted ensemble model showed the best accuracy
160 in the separated test set (Fig. 2-C, D and Supplement table 4). An ensemble is a
161 collection of models whose predictions are combined by the weighted averaging or
162 voting²¹. In our case, it is constructed from 11 selected models (Fig. 2-E). The feature
163 importance of the weighted ensemble model was measured by permutation
164 (Supplement table 5). *NT5E* (also referred to as *CD73*), which is among the top ranked
165 features, was reported related to NAD metabolism and calcification of joints and
166 arteries²², and *CRYGS*-decreased in the age-related nuclear cataracts²³.

167

168 **4. Linear Aging Clock Predicts Quick- and Slow-aging Population, Respectively.**

169 A simpler model can provide a better interpretation and a lower expected risk in
170 the application. The Linear Model_2 showed second-best accuracy (Fig. 2-D) while its
171 structure was much simpler than the ensembled model (Fig. 2-E). Thus, we applied
172 more tactile parameter searches by elastic-net for a linear model as a substitute for the
173 ensemble model (See Method and FigS3-A & Supplement table 6) and yielded the best
174 model with an MAE of 5.02 and 0.54 in the separated test set (Fig. 3-A, B). The model
175 remained accurate upon the down-sampling of genes. Sampling and the broken-stick
176 test were applied to find a reduced model with fewer genes, which estimated a turning
177 point of 219 genes. A reduced model could achieve an MAE of 5.37 with 200 genes
178 (FigS3-C). This model outperformed the previous blood transcriptome-based aging
179 clock constructed in ribo-minus PBMC²⁴ (MAE=5.68) and multiple cohort model
180 constructed in whole-blood gene expression array data⁶ (MAE=7.8), as well as other

181 transcriptome-based aging clocks constructed in muscle gene expression⁷ (MAE=6.24).

182 Prediction of the aging clock was used to define the aging rate. As commonly
183 suggested by previous studies, the difference between the model predicted age and
184 chronological age was used to evaluate the personal status of aging⁹. The prediction
185 error distribution was adjusted for age and data set differences (Fig S3-B, D). The
186 population was classified into average, quick-aging, and slow-aging groups (Fig. 3-C).
187 Then we asked if the blood test result and immune cell composition differed in quick-
188 aging and slow-aging populations. As blood test results showed, the slow-aging group
189 showed a significantly higher lymphocyte count (p-value = 0.0049, Wilcoxon test) and
190 significantly lower granulocyte count (p-value = 0.014, Wilcoxon test) (Fig. 3-D, E),
191 indicating a younger blood cell count phenotype²⁵. Then we applied Cibersortx²⁶, an
192 approach for digital cytometry, and its built-in blood immune cell signature LM22²⁷ to
193 deconvolute the immune cell composition. The quick-aging population had much more
194 neutrophils (p-value = 9.8e-06, Wilcoxon test), less CD8 T cells (p-value = 0.041,
195 Wilcoxon test), and less resting memory CD4 T cells (p-value = 0.017, Wilcoxon test).
196 The decreased numbers of CD8 T cells and resting memory CD4 T cells with age were
197 consistent with the previous studies^{25,28}. Altogether, the linear-based aging clock could
198 effectively estimate an aging rate through general model searching, capture the
199 systematic aging change pattern to a degree, and be applied to distinguish quick- and
200 slow-aging populations for future use.

201

202 **5. Aging Transcriptome Undergoes a Fluctuation with a Crest around 40**

203 From the general trajectory above (Fig. 1-B), the non-linear dimension of aging
204 was shown yet often went unnoticed in researches with a two-group design. A recent
205 study in human plasma proteome revealed waves of changes in the fourth, seventh, and
206 eighth decades¹⁰. We wondered if there was a similar pattern at the transcriptional level.
207 Genes with significant changes in a window period of 20 were identified by Differential
208 Expression-Sliding Window Analysis (DE-SWAN)¹⁰. The algorithm takes gene
209 expression within a window of 20 years. It compares two groups in parcels of 10 years
210 (*e.g.*, 30-40 years old compared to 40-50 years old) by routine differential expression

211 analysis while sliding from young to old at a step size of 1 year. Gene expression
212 changes at middle age were captured by the sliding window successively. The age
213 distribution (Supplement Fig. 1-A) showed that the center age was restricted in the 30-
214 60 range when analyzed from 20 to 60. The significantly changed genes around the
215 center age with different p-value cutoffs were summarized (Fig. 4-A). Intriguingly,
216 there was a crest at the age of 40, corresponding to the finding at the protein level. The
217 crest remained robust at the different window sizes (Fig. S4-B, E). The genes with
218 significant changes ($p < 0.05$) at the age of 40 were named Wave ARGs (Supplement
219 table 7), whose definition is different from Linear ARGs. Notably, 22 upregulated
220 Linear ARGs were downregulated at the age of 40, and 23 genes *vice versa*. Apart from
221 the biological processes Linear-ARGs involving in, enrichment analysis showed that
222 (Supplement table 8) the Wave ARGs down-associated with age took part in respiratory
223 electron transport. At the same time, the Wave ARGs up-associated with age were
224 enriched in actin filament-based process and Rho-GTPase signaling (Fig. 4-C). Among
225 the top Wave ARGs, *MXDI*, encoding a member of the MYC/MAX/MAD network of
226 leucine zipper transcription factors²⁹, was involved in the regulation of telomerase³⁰.
227 However, *MXDI* was not identified by linear analysis though it showed a significant
228 upward trend around the age of 40 (adjusted p-value = 0.01, ANOVA test with sex as
229 covariance, Benjamini-Hochberg method). Therefore, the aging transcriptome showed
230 fluctuation with a crest around 40.

231

232 **6. Aging Transcriptome Fluctuation Differed in the Quick- and Slow-aging** 233 **Populations**

234 We then asked if the crest were different between a quick-aging population and a
235 slow one. The same sliding window analysis was conducted on the quick-aging and
236 slow-aging populations, respectively. In the quick-aging group, more dysregulated
237 genes were identified at age 39, indicating that the crest came earlier and was more
238 vigorous. However, less changed genes were found in the slow-aging group with the
239 crest at age 41 (Fig. 4-D). The pattern remained robust with the different window sizes
240 (Fig S4-A, C, D, F).

241 Furthermore, the changed magnitude between the quick-aging and the slow-aging
242 group differed, such as the changed center shifting to the younger in the quick-aging
243 group (Fig. 4-E). The crest in the quick-aging group was dramatic, so we conducted the
244 enrichment analysis on these genes. The downregulated genes were involved in
245 oxidative phosphorylation, regulation of intrinsic apoptotic pathway by p53, and the
246 response of EIF2AK4 to amino acid deficiency. On the other hand, the upregulated
247 genes were enriched in leukocyte activation, and RHO GTPases activate PAKs and
248 G2/M transition of the mitotic cell cycle (Fig. 4-F, Supplement table 9). Altogether,
249 these results showed that the aging transcriptome fluctuation at age 40 differed between
250 the quick-aging and the slow-aging populations.

251

252 **7. Model-based Assessment for Geroprotective Molecules**

253 Numerous researches have been conducted in a quest for anti-aging intervention³¹.
254 Epigenomic clocks, not the transcriptome-based ones, have been applied in the
255 quantitative assessment of the rejuvenation effect³². Therefore, we applied the aging
256 clock to assess the individual responses to star geroprotective molecules. Blood samples
257 were collected from 8 volunteers, the same as the Method the extensive cohort above
258 (Supplementary Fig. 5-A). Four of the collected blood samples were treated with LPS
259 and then examined the mRNA expression of TNF compared with controls by the qPCR
260 analysis (Supplementary Fig. 5-B). As expected, the TNF expression is significantly
261 induced after the LPS treatment (T-paired test, $p=0.005$), showing that the blood
262 samples were still responsive to external stimulations. Then, five geroprotective
263 molecules were chosen to treat blood samples for 24 hours, including Metformin³³,
264 NMN²⁶, Resveratrol³⁴, Aspirin³⁵, and Curcumin³⁶, followed by the sequencing and
265 evaluation by the aging clock after QC and pre-processing (See Method) to compare
266 the predicted ages between treated ones and paired controls (Fig 5-A). The Metformin-
267 treated and NMN-treated ones were predicted to be significantly younger (Metformin:
268 3 paired sample, t paired test: $p=0.031$; NMN: 6 paired sample, paired t-test: $p=0.033$,
269 Fig 5-B).

270 In contrast, no significant reductions in the treated groups, using Resveratrol,

271 Aspirin, or Curcumin, were observed (Fig. 5-B, C). The individual responses to
272 different geroprotective molecules also differed in the predicted age-reduction scale.
273 For example, the blood sample (#P44) responded best to Metformin while the #P30 one
274 showed the best response to NMN while P14 and P29 ones responded poorly to all
275 treated molecules (Fig. 5-D). KEGG³⁷ pathway enrichment scores were calculated for
276 each sample, and the drifts between control and treated samples were observed. The
277 drifts were further compared among individuals to evaluate the anti-aging effect. The
278 Metformin-treated samples generally had a higher enrichment in Lysine degradation
279 (KDAC) pathway and lower enrichments in nuclear factor-kB (NF-kB), forkhead box
280 transcription factors (FOXO), and tumor necrosis factor (TNF) pathways, in agreement
281 with its molecular mechanism in aging³⁸. The Nicotinate and nicotinamide metabolism
282 pathways were generally augmented in NMN-treated samples, accompanied by
283 decreased enrichment of NF-kB and TNF pathways. The Resveratrol-treated samples
284 with the effective responses had an attenuated enrichment in FOXO, NF-kB, TNF, p53,
285 and protein-processing in endoplasmic reticulum pathways³⁹, while the ineffective ones
286 showed an opposite drift (Fig. 5-B). The enriched 5-monophosphate-activated protein
287 kinase (AMPK) and oxidative phosphorylation pathways were identified in Aspirin-
288 treated samples of the affected group. The curcumin-treated samples showed decreased
289 enrichment in mammalian target of rapamycin (mTOR), FOXO, transforming growth
290 factor β (TGF- β), NF-kB, and TNF pathways, while samples in the ineffective group
291 did not (Supplementary Fig 5-C). These results provided a molecular view for the
292 different individual responses, and the aging clock predicted a younger age after the
293 Metformin- and NMN-treated samples.

294

295

296 **Discussion:**

297 The study deeply mined the aging blood transcriptome, revealed the underlying
298 midlife change in gene expression, and constructed an ensemble aging clock and a more
299 straightforward linear aging clock, which shows the promising application in predicting
300 personalized drug rejuvenation effect.

301 This study identified a pool of age-related genes. It should be noted that these
302 Linear ARGs presented in this study depend on this cohort, which is the genetic
303 background of the Eastern Chinese population. A meta-analysis demonstrated that the
304 aging transcriptome signature displayed low overlap in different genetic backgrounds,
305 such as native, Hispanic, and African American⁶. Although a universal aging pattern is
306 desirable, aging biomarkers specific to a particular genetic background population
307 should be studied. Therefore, the Linear ARGs, together with gender, were used as
308 features for the aging clock. A study showed that the aging biomarkers were population-
309 specific for South Korean, Canadian, and Eastern European so that aging clocks for
310 each population were built up⁴⁰. Although the ethnic background should be considered
311 when constructing aging clocks, part of the aging pattern and the general methodology
312 should be consistent.

313 An ensemble LDA model was built in a recent study⁸ and showed better
314 performance in an age bin approach, indicating the ensemble model is a promising
315 structure. For a complex process with linear and non-linear changes, such as aging, a
316 general ensemble model combining linear and non-linear models is a suitable structure.
317 In this study, the ensemble model showed a slight advantage in accuracy compared to
318 the elastic net-based model. However, for simplicity in interpretation and application,
319 the elastic net-based linear model was chosen. This may be due to the relatively small
320 cohort size (505) and sample distribution. Although the cohort covered an age range of
321 18 to 68 and the median age of 36, the old samples were insufficient. Therefore, a more
322 extensive and comprehensive cohort is necessary for future study.

323 The division of quick- and slow-aging populations was clinically meaningful for
324 risk evaluation, treatment, and personalized anti-aging therapy. The immune cell
325 composition of the quick-aging group shift toward an older phenotype. Neutrophils-
326 Lymphocyte ratio (NLR) is a well-accepted marker for systematic inflammation related
327 to the prognosis of cancer⁴¹, cardiovascular diseases, and all-cause mortality⁴². The
328 quick-aging group displayed higher Neutrophils and lower Lymphocyte count,
329 indicating a higher degree of systematic inflammation. Transcriptome-based aging
330 clocks have an advantage in interpretability. Thus, it can be used for long-term

331 monitoring, such as physical examination, and provide other information along with
332 the aging clock.

333 In the non-linear dimension of aging, the patterns of gene expression undergo
334 dynamic changes throughout life. The fluctuation should be considered when gene
335 signatures are for diagnostic purposes, improving the specificity and accuracy. Modules
336 mapping gene changes (Fig. 1) were associated with the hallmark activities in aging.
337 The gene expression variances in life suggested the role of environmental factors,
338 mental health⁴³, and other soft factors apart from the genetic programming (the hard
339 factor) in aging, especially in the midlife change. The quick-aging group showed an
340 earlier and more prominent for the aging change. However, our findings showed that
341 early anti-aging interventions in midlife, more investigations on these age-related Wave
342 genes of the quick-aging group aid in dissecting the heterogeneous aging process.

343 The aging clock succeeded in evaluating the rejuvenation effect of molecules such
344 as NMN and Metformin *in vitro*. The aging clock was applied to control and paired
345 drug-treated samples to get the relative age prediction. The method can be applied for
346 *in vitro* screening for anti-aging interventions. Most treated blood samples of
347 responsive individuals showed the enriched signaling pathways involved in the
348 molecular mechanism related to aging. Consistently, the treated ones with the poorly
349 responses showed the opposite enrichment, displaying the enriched inflammatory
350 pathways.

351 Moreover, these results indicated that each person could respond differently to
352 each molecule, as their responses to the molecular targets and the related mechanisms
353 vary. Thus, the aging clock can be used to determining the most suitable drugs.
354 However, these observations may need to be further validated considering the limited
355 samples. Therefore, we aim to develop an aging clock by investigating the
356 transcriptome landscape of age-related diseases on more samples in the future.

357

358

359

360

361

362 **Methods:**

363 **Blood Sample Acquisition and RNA-seq**

364 Blood samples were drawn from people coming for physical examination.
365 Approval for utilizing the samples was obtained from the Ethics Committee of the
366 Second Affiliated Hospital, School of Medicine, Zhejiang University (Approval
367 Reference Number: 2019-234). Next, samples were first treated with ACK Lysis Buffer
368 (Solarbio, China). Samples were processed for RNA-seq, which was modified from a
369 previous method⁴⁴. Blood samples were first lysed by Trizol reagent (TAKARA). Then,
370 reverse transcription was conducted using SuperScript II reverse transcriptase
371 (Invitrogen), and double-strand cDNA was synthesized using NEBNext mRNA second
372 strand synthesis kit (NEB). Cleaning was done using AMPure XP beads (Beckman
373 Coulter), and the sequencing library was constructed using the Nextera XT
374 kit(Illumina). The pooled library was sequenced on the Illumina X-Ten platform. RNA-
375 seq reads data were mapped to the reference genome using STAR⁴⁵. Expression was
376 calculated with counts per million (CPM).

377

378 **Cell Culture**

379 Whole blood samples from 8 individuals were randomly selected for treatment and
380 culture. Each sample was divided into six portions (100 μ l each, some samples had less
381 than six due to the limit volume of blood) and were added to the 48-well plate
382 (Supplementary Fig 5-A). Six replicates of each person were added different reagents
383 at reported concentrations (100 μ M Aspirin⁴⁶(Selleck, S3017), 50 μ g/ml
384 Curcumin⁴⁷(Selleck, S1039), 50 μ M Resveratrol⁴⁸(Selleck, S1396), 500 μ M NMN⁴⁹
385 (Qingyuan Shengyi Biological Technology Co., Ltd.), 100 μ M Metformin⁵⁰(Selleck,
386 S1950), 100ng/ml LPS(Sigma, L2880) respectively. Then these samples were
387 incubated and constantly rotated on a shaker at 6 rpm, 37°C for 24 hours⁵¹. Then these
388 samples were harvested and washed with ACK lysis buffer (Solarbio, China) three
389 times to remove the erythrocytes before RNA-seq mentioned above.

390

391 **Data Quality Control**

392 Samples with total CPM three times the mean absolute deviation higher or lower
393 away from the medium were filtered. For the large cohort, samples with age three times
394 the mean absolute deviation higher or lower away from the medium were filtered.
395 Moreover, we only kept genes that were expressed in at least 10% of all samples.
396 Supplementary Fig 1-B, C showed the library size and number of the expressed gene
397 of the large cohort.

398

399 **Enrichment Analysis**

400 To determine the biological meaning of a group of genes, we queried GO and
401 Reactome terms using Metascape¹⁸.

402

403 **Clustering of Gene Expression Trajectories**

404 To estimate trajectories of age-related genes (roughly selected by person
405 correlation score > 0.05) during aging, the expression trajectories of 4318 genes are
406 fitted by loess. To reduce the complexity in changing patterns, the trajectories were
407 clustered by unsupervised hierarchical clustering. Genes with similar changing patterns
408 were poured into the same module. To understand the biological functions of each
409 cluster, we queried GO databases, using R clusterProfiler package⁵² and org.Hs.eg.db
410 package⁵³.

411

412 **Linear Fitting and Linear ARGs of the Blood Transcriptome**

413 Linear fitting was done by glm function in the R stats package and gaussian family.
414 For each gene, the linear model fits as follow:

$$415 \quad g_i \sim age + sex$$

416 The square sum of was calculated by the aov function in the R stats package. The
417 percentages of variance explained by sex and age for each gene were computed in the
418 form of :

$$419 \quad partial\ eta2 = \frac{Sum\ of\ Square_{effect}}{(Sum\ of\ Square_{effect} + Sum\ of\ Square_{error})}$$

420 The age effect for each gene was determined by the two-side p-value of t-test in
421 `summary.lm` function in R stats package. Genes with a significant age effect (p-
422 value >0.05) were considered as Linear ARGs.

423

424 **Construction of Aging Clock**

425 AutoGluon²⁰ is an open-source auto-machine learning framework, and the
426 AutoGluon-Tabular, which was designed for structured data, was applied for model
427 searching (python 3.8.5, autogluon 0.2.0). The cohort was first divided as train set and
428 test set with a ratio of 3:1, and then the train set was further divided, 80% of which was
429 used for model construction and 20% of which (validation set) was used for model
430 validation in a search for the best model. The train and test set were separately scaled
431 and centered in preprocessing step. 1138 Linear ARGs and gender were used as model
432 features. The models were trained in MAE (mean absolute error) and tested in MAE
433 and other metrics. The hyperparameters space was expanded from default and stated in
434 the supplementary data.

435 The Elastic-net model was built in R (4.0.5) by the `glmnet` package. The `cv.glmnet`
436 function was used for the parameter lambda search with 20 fold cross-validation and
437 MAE as measuring metric. An outer loop of 10-fold cross-validation was applied for
438 an average MAE. Parameter alpha was determined by grid search and the best average
439 MAE. The final model was constructed by the best alpha with correspondent lambda.

440

441 **Aging rate and Quick/Slow Aging Population Distinguishment**

442 Aging clock prediction was used for aging rate estimation and was calculated with
443 the difference between the model predicted age and chronological age:

$$444 \quad \Delta Age = Age_{Predicted} - ActualAge$$

445 Considering the prediction error distribution, it was adjusted for age itself, and the
446 data set difference. (0-train set, 1- test set)

$$447 \quad \Delta Age_{curated} = \Delta Age - loess(\Delta Age \sim Age + Set), Set = 0,1$$

448 With the curated aging rate, the population was further classified into average,
449 quick-aging, and slow-aging groups. q_1, q_2, q_3 were the ascending quantile numbers of

450 the curated aging rate of the cohort. People with $\Delta Age_{curated} > q_3$ was classified into
451 the quick-aging group and people with $\Delta Age_{curated} < q_1$ were classified into slow-
452 aging group.

453

454 **Sliding Window Analysis**

455 DE-SWAN¹⁰ was used with gender as covariant, and the bin size of 10 and 15 was
456 tested. The number of significantly changed gene in the window were summarized.

457

458 **Model Assessment in Cultured Sample**

459 The gene expression matrix was first scaled and centered to gaussian distribution.
460 Then the gender information was appended. The samples were predicted by the elastic-
461 net-based model. The predicted ages of the treated and control sample were compared
462 by paired t-test.

463

464 **KEGG Pathway Enrichment Analysis**

465 The gsva function of R package GSVA⁵⁶ was utilized with parameters as follows:
466 min.sz of 5, max.sz of 500, “ssgsea” method, abs.ranking and other default parameters.
467 The KEGG gene sets were obtained from the KEGG pathway database of release 99.1.

468

469 **Data Availability:**

470 All the data generated in this study are available upon reasonable request to the
471 corresponding author.

472

473 **Code Availability**

474 All the codes generated in this study are available upon reasonable request to the
475 corresponding author.

476

477 **Author Contributions**

478 X.S.: Study design, data analysis, sample processing and manuscript writing; B.W.:
479 Study design, acquisition of clinical sample, sample processing; W.J.: Data analysis,

480 sample processing and manuscript writing; Y.L., N.N., L.G., Y.L.: Sample processing;
481 Y.Z.: Acquisition of clinical sample; K.Z.: Data analysis; J.L.: Manuscript revision; J.J.:
482 Acquisition of clinical sample and design; X.Z., H.O.: Conception and design .

483

484 **Acknowledgement**

485 This work was supported by National Key R&D Program of China
486 (2017YFA0104900); National Natural Science Foundation of China (81871127,
487 8217060567, 31870973); Zhejiang Medical and Health Science and Technology
488 Program (2013KYB080); Science and Technology program of Jinhua Science and
489 Technology Bureau (Grant No. 2021-3-001)

490

491 **Competing interests:**

492 The authors declare no competing interests.

493

494 **References:**

- 495 1. United Nations, Department of Economic and Social Affairs, Population Division
496 (2019). World Population Prospects 2019: Highlights. ST/ESA/SER.A/423.
- 497 2. López-Otín, C., Blasco, M. A., Partridge, L., Serrano, M. & Kroemer, G. The
498 hallmarks of aging. *Cell* **153**, 1194–1217 (2013).
- 499 3. Alpert, A. *et al.* A clinically meaningful metric of immune age derived from
500 high-dimensional longitudinal monitoring. *Nat. Med.* **25**, 487–495 (2019).
- 501 4. Sayed, N. *et al.* An inflammatory aging clock (iAge) based on deep learning
502 tracks multimorbidity, immunosenescence, frailty and cardiovascular aging. *Nat.*
503 *Aging* **1**, 598–615 (2021).
- 504 5. Valdes, A. M., Glass, D. & Spector, T. D. Omics technologies and the study of
505 human ageing. *Nat. Rev. Genet.* **14**, 601–607 (2013).
- 506 6. NABEC/UKBEC Consortium *et al.* The transcriptional landscape of age in
507 human peripheral blood. *Nat. Commun.* **6**, 8570 (2015).
- 508 7. Mamoshina, P. *et al.* Machine Learning on Human Muscle Transcriptomic Data
509 for Biomarker Discovery and Tissue-Specific Drug Target Identification. *Front.*
510 *Genet.* **9**, 242 (2018).
- 511 8. Fleischer, J. G. *et al.* Predicting age from the transcriptome of human dermal
512 fibroblasts. *Genome Biol.* **19**, 221 (2018).
- 513 9. Xia, X., Wang, Y., Yu, Z., Chen, J. & Han, J.-D. J. Assessing the rate of aging to
514 monitor aging itself. *Ageing Res. Rev.* **69**, 101350 (2021).
- 515 10. Lehallier, B. *et al.* Undulating changes in human plasma proteome profiles across
516 the lifespan. *Nat. Med.* **25**, 1843–1850 (2019).

- 517 11. Elliott, M. L. *et al.* Disparities in the pace of biological aging among midlife
518 adults of the same chronological age have implications for future frailty risk and
519 policy. *Nat. Aging* **1**, 295–308 (2021).
- 520 12. Kevei, É. & Hoppe, T. Ubiquitin sets the timer: impacts on aging and longevity.
521 *Nat. Struct. Mol. Biol.* **21**, 290–292 (2014).
- 522 13. Márquez, E. J. *et al.* Sexual-dimorphism in human immune system aging. *Nat.*
523 *Commun.* **11**, 751 (2020).
- 524 14. Kauppila, T. E. S., Kauppila, J. H. K. & Larsson, N.-G. Mammalian
525 Mitochondria and Aging: An Update. *Cell Metab.* **25**, 57–71 (2017).
- 526 15. Turi, Z., Lacey, M., Mistrik, M. & Moudry, P. Impaired ribosome biogenesis:
527 mechanisms and relevance to cancer and aging. *Aging* **11**, 2512–2540 (2019).
- 528 16. Austad, S. N. & Fischer, K. E. Sex Differences in Lifespan. *Cell Metab.* **23**,
529 1022–1033 (2016).
- 530 17. Zhang, W. *et al.* A single-cell transcriptomic landscape of primate arterial aging.
531 *Nat. Commun.* **11**, 2202 (2020).
- 532 18. Zhou, Y. *et al.* Metascape provides a biologist-oriented resource for the analysis
533 of systems-level datasets. *Nat. Commun.* **10**, 1523 (2019).
- 534 19. Golomb, L., Volarevic, S. & Oren, M. p53 and ribosome biogenesis stress: The
535 essentials. *FEBS Lett.* **588**, 2571–2579 (2014).
- 536 20. Erickson, N. *et al.* AutoGluon-Tabular: Robust and Accurate AutoML for
537 Structured Data. *ArXiv200306505 Cs Stat* (2020).
- 538 21. Caruana, R., Niculescu-Mizil, A., Crew, G. & Ksikes, A. Ensemble selection
539 from libraries of models. in *Twenty-first international conference on Machine*
540 *learning - ICML '04* 18 (ACM Press, 2004). doi:10.1145/1015330.1015432.
- 541 22. Hilaire, C. S. *et al.* NT5E Mutations and Arterial Calcifications. *N Engl J Med* **11**
542 (2011).
- 543 23. Su, S. *et al.* Proteomic Analysis of Human Age-related Nuclear Cataracts and
544 Normal Lens Nuclei. *Investig. Ophthalmology Vis. Sci.* **52**, 4182 (2011).
- 545 24. Xia, X. *et al.* Three-dimensional facial-image analysis to predict heterogeneity of
546 the human ageing rate and the impact of lifestyle. *Nat. Metab.* **2**, 946–957 (2020).
- 547 25. Qin, L. *et al.* Aging of immune system: immune signature from peripheral blood
548 lymphocyte subsets in 1068 healthy adults. *Aging* **8**, 848–859 (2016).
- 549 26. Newman, A. M. *et al.* Determining cell type abundance and expression from bulk
550 tissues with digital cytometry. *Nat. Biotechnol.* **37**, 773–782 (2019).
- 551 27. Newman, A. M. *et al.* Robust enumeration of cell subsets from tissue expression
552 profiles. *Nat. Methods* **12**, 453–457 (2015).
- 553 28. Zheng, Y. A human circulating immune cell landscape in aging and COVID-19.
554 **31** (2020).
- 555 29. Cascón, A. & Robledo, M. MAX and MYC: A Heritable Breakup: Figure 1.
556 *Cancer Res.* **72**, 3119–3124 (2012).
- 557 30. Schaefer, C. F. *et al.* PID: the Pathway Interaction Database. *Nucleic Acids Res.*
558 **37**, D674–D679 (2009).
- 559 31. Partridge, L., Fuentealba, M. & Kennedy, B. K. The quest to slow ageing through
560 drug discovery. *Nat. Rev. Drug Discov.* **19**, 513–532 (2020).

- 561 32. Fahy, G. M. *et al.* Reversal of epigenetic aging and immunosenescent trends in
562 humans. *Aging Cell* **18**, (2019).
- 563 33. Cabreiro, F. *et al.* Metformin Retards Aging in *C. elegans* by Altering Microbial
564 Folate and Methionine Metabolism. *12*.
- 565 34. Baur, J. A. & Sinclair, D. A. Therapeutic potential of resveratrol: the in vivo
566 evidence. *DRUG Discov.* *14*.
- 567 35. McNeil, J. J. *et al.* Effect of Aspirin on Cardiovascular Events and Bleeding in
568 the Healthy Elderly. *N. Engl. J. Med.* **379**, 1509–1518 (2018).
- 569 36. Zia, A., Farkhondeh, T., Pourbagher-Shahri, A. M. & Samarghandian, S. The role
570 of curcumin in aging and senescence: Molecular mechanisms. *Biomed.*
571 *Pharmacother.* **134**, 111119 (2021).
- 572 37. Kanehisa, M., Furumichi, M., Sato, Y., Ishiguro-Watanabe, M. & Tanabe, M.
573 KEGG: integrating viruses and cellular organisms. *Nucleic Acids Res.* **49**, D545–
574 D551 (2021).
- 575 38. Torres, W. *et al.* Anti-Aging Effect of Metformin: A Molecular and Therapeutical
576 Perspective. *Curr. Pharm. Des.* **26**, 4496–4508 (2020).
- 577 39. Zhou, D.-D. *et al.* Effects and Mechanisms of Resveratrol on Aging and Age-
578 Related Diseases. *Oxid. Med. Cell. Longev.* **2021**, 1–15 (2021).
- 579 40. Mamoshina, P. *et al.* Population Specific Biomarkers of Human Aging: A Big
580 Data Study Using South Korean, Canadian, and Eastern European Patient
581 Populations. *J. Gerontol. Ser. A* **73**, 1482–1490 (2018).
- 582 41. Templeton, A. J. *et al.* Prognostic Role of Neutrophil-to-Lymphocyte Ratio in
583 Solid Tumors: A Systematic Review and Meta-Analysis. *JNCI J. Natl. Cancer Inst.*
584 **106**, (2014).
- 585 42. Wang, X. *et al.* Neutrophil to lymphocyte ratio in relation to risk of all-cause
586 mortality and cardiovascular events among patients undergoing angiography or
587 cardiac revascularization: A meta-analysis of observational studies. *Atherosclerosis*
588 **234**, 206–213 (2014).
- 589 43. Wertz, J. *et al.* Association of History of Psychopathology With Accelerated
590 Aging at Midlife. *JAMA Psychiatry* **78**, 530 (2021).
- 591 44. Picelli, S. *et al.* Smart-seq2 for sensitive full-length transcriptome profiling in
592 single cells. *Nat. Methods* **10**, 1096–1098 (2013).
- 593 45. Dobin, A. *et al.* STAR: ultrafast universal RNA-seq aligner. *Bioinforma. Oxf.*
594 *Engl.* **29**, 15–21 (2013).
- 595 46. Vitale, P. *et al.* Synthesis, Pharmacological Characterization, and Docking
596 Analysis of a Novel Family of Diarylisoxazoles as Highly Selective Cyclooxygenase-
597 1 (COX-1) Inhibitors. *J. Med. Chem.* **56**, 4277–4299 (2013).
- 598 47. Li, N. *et al.* Curcumin and Curcumol Inhibit NF- κ B and TGF- β ₁/Smads
599 Signaling Pathways in CSE-Treated RAW246.7 Cells. *Evid. Based Complement.*
600 *Alternat. Med.* **2019**, 1–9 (2019).
- 601 48. Mai, A. *et al.* Study of 1,4-Dihydropyridine Structural Scaffold: Discovery of
602 Novel Sirtuin Activators and Inhibitors. *J. Med. Chem.* **52**, 5496–5504 (2009).
- 603 49. Penke, M. *et al.* Oleate ameliorates palmitate-induced reduction of NAMPT
604 activity and NAD levels in primary human hepatocytes and hepatocarcinoma cells.

- 605 *Lipids Health Dis.* **16**, 191 (2017).
- 606 50. Suh, D. H., Lee, S., Park, H.-S. & Park, N. H. Medroxyprogesterone Reverses
607 Tolerable Dose Metformin-Induced Inhibition of Invasion via Matrix
608 Metalloproteinase-9 and Transforming Growth Factor- β 1 in KLE Endometrial Cancer
609 Cells. *J. Clin. Med.* **9**, 3585 (2020).
- 610 51. Orecchioni, M. *et al.* Single-cell mass cytometry and transcriptome profiling
611 reveal the impact of graphene on human immune cells. *Nat. Commun.* **8**, 1109 (2017).
- 612 52. Yu, G., Wang, L.-G., Han, Y. & He, Q.-Y. clusterProfiler: an R package for
613 comparing biological themes among gene clusters. *Omic J. Integr. Biol.* **16**, 284–287
614 (2012).
- 615 53. Carlson, M. org.Hs.eg.db: Genome wide annotation for Human. (2019)
616 doi:10.18129/B9.bioc.org.Hs.eg.db.
- 617
- 618

619 **Figure legend**

620 **Figure 1. Trajectories of gene expression throughout age form functional**

621 **modules.**

622 (A) Hierarchical clustering of gene expression trajectories. A red box highlighted each
623 cluster.

624 (B) Eight clusters of the aging pattern (five up-regulated, three down-regulated,
625 respectively). Redline was indicating the fitting curve created by loess.

626 (C) Top GO terms in which each aging pattern is involved. Color showing the p
627 adjusted value of enrichment analysis. Dot size showing the number of genes hit by
628 GO terms.

629

630 **Figure 2. The construction of the ensemble model as the aging clock.**

631 (A) Volcano plot shows age-related gene discovered by linear fitting (Linear ARGS).
632 (p-value <0.05, 608 of which up with age and 530 of which down with age) X-axis
633 showed signed log10 of linear fitting coefficient; y-axis showed negative of log10 of
634 the p-value.

635 (B) Heat map of pathway enriched for the age-related gene in GO and Reactome
636 terms.

637 (C) Performance of models constructed by AutoGulon. MAE is for mean absolute
638 error. The X-axis shows time latency for inference. Y-axis shows model performance
639 measured in the MAE validation set.

640 (D) Performance metrics in top10 models. R2: R squared, test: test set, Val: validation
641 set. The whole table is in supplementary data.

642 (E) Models that contribute to ensemble WeightedEnsemble_L2 model. The score is
643 negative MAE, as the algorithm selects the model by the rule that the model with a
644 higher score is better than the control.

645

646 **Figure 3. Construction of Biological-meaningful Aging Clock predicted**
647 **population-based Quick-aging and Slow-aging group.**

648 (A) Aging clock constructed visualized with actual age against predicted age. (each

649 dot represents a person, black dots: samples used in training, red dots: samples used in
650 the validation)

651 (B) Performance metrics in the regression model. MAE: mean absolute error, R2: R
652 squared. Correlation: Pearson correlation score.

653 (C) Aging clock colored with “Quick-aging” and “Slow-aging” population defined as
654 delta group. Top indicating predicted Quick-aging with curated delta age in the top
655 quarter of the population, bottom indicating predicted Slow-aging with curated delta
656 age in last quarter of the population.

657 (D)-(I) Box plot shows the contrast of cell fraction calculated by deconvolution(F-I)/
658 cell count in blood test(D-E) between predicted Quick-aging and Slow-aging
659 population. (Wilcoxon test)

660

661 **Figure 4. Undulating aging transcriptome with a peak around 40.**

662 (A) Count of genes with significant changes around a certain age. (p-value, ANOVA
663 test)

664 (B) Circus plot showing the overlap in WaveARG and LinearARG. (in both up and
665 down direction, p-value < 0.05)

666 (C) Heat map showing GO term enriched for WaveARG discovered in comparison
667 with LinearARG.

668 (D) Count of genes with significant changes peaks at different ages in groups
669 identified by the model (i.e., Quick-Aging group, Slow-Aging group, and Average).

670 Quick-Aging group peaks at 39, while Average peaks at 40 and Slow-Aging group
671 peaks at 41. (q: adjusted p-value, Benjamini-Hochberg method, $q < 0.1$)

672 (E) Heat map showing general changes in transcriptome during aging in Quick-Aging
673 group and Slow-Aging group. Signed $-\log_{10}(\text{FDR})$ were used as heat map value. The
674 white dash line marked age 40.

675 (F) Heat map showing GO term enriched for WaveARG in Quick-Aging Group.

676


677 **Figure 5. Model-based assessment for individual responses to known**
678 **geroprotective molecules.**

679 (A) Graphic summary for the drug intervention and assessment pipeline.
680 (B) Box plots show the model's prediction of the samples treated with different
681 molecules compared with control. (Paired t-test and the alternative hypothesis was the
682 predicted age of control samples were less than the treated samples). Heatmaps of
683 enrichment score of known KEGG pathways involved in specific drugs. The columns
684 were grouped in treated and control samples of the same person (Id started with P) to
685 see the drug effect. The drifts were further compared between individuals on whom
686 the drug was evaluated to have an anti-aging effect or not.
687 (C) Box plots show the model's prediction of the samples treated with different
688 molecules compared with control. (Paired t-test and the alternative hypothesis was the
689 predicted age of control samples were less than the treated samples).
690 (D) Radar charts show individual response heterogeneity to different geroprotective
691 molecules. Blue: treated sample was predicted younger than the control. Red: treated
692 sample was predicted older than the control. The value of radius was the predicted age
693 difference between the treated samples and the controls.

694 **Figure 6. Graphical Summary**


695

696 **Figure 1**



697


698 **Figure 2**



699


700

701 **Figure 3**




702

703 **Figure 4**



704


705 **Figure 5**



706

707 **Figure 6**

708



709

710 **Supplementary data legend**

711 **Figure S1. Cohort characterization of Chinese population across the life span**

712 (A) Histogram shows sample distribution in this cohort.

713 (B) Histogram shows sample's library size distribution of the RNA sequencing data.

714 (C) Histogram shows sample's number of expressed genes distribution of the RNA
715 sequencing data.

716

717 **Figure S2. The association of Linear Age-related Genes (Linear ARGs) with**
718 **previous studies and sex.**

719 (A) Venn plot of LinearARGs and genes reported in the previous meta-study with
720 direction.

721 (B-C) Percentage of variance explained by age and sex in the linear fitting. (ANOVA
722 test, Sum of square)

723

724 **Figure S3. Characterization of Aging Clock modeling.**

725 (A) Relationship between lambda and train error for elastic-net modeling. In this
726 study, lambda of minimum mean absolute error (MAE) is picked.

727 (B) The correlation between actual age and delta-age in a model before and after
728 model curation for age.

729 (C) Relationship between MAE in the test set and the number of genes in the model,
730 of which 219 is the turning point. (Genes are selected according to the rank of p-value
731 in figure 2)

732 (D) The difference of delta-age between training and testing data set in a model before
733 (left) and after (right) model curation for data set.

734

735 **Figure S4. Wave ARGs distribution in different window sizes across the group.**

736 (A-C) Changes in the number of genes experienced significant changes in a window
737 size of 20 (bin size is half of the window size, thus window size of 20, the bin size is
738 10. The figures show gene changes in $-10 \sim +10$ around center age).

739 (D-F) Changes in the number of genes experienced significant changes in a window

740 size of 30 (-15 ~ +15).

741

742 **Figure S5. Characterization of molecule-treated samples.**

743 (A) Table of the existed sample. (1 - sample existed, 0 - sample not existed). The
744 sample not existed is lost due to technical error.

745 (B) Box plot shows the qPCR relative expression of TNF in LPS treated sample in
746 comparison with control. (Paired t-test)

747 (C) Heatmap of enrichment score of known KEGG pathways involved in Aspirin and
748 Curcumin. The columns were grouped in treated and control samples of the same
749 person (Id started with P) to see the drug effect. The drifts were further compared
750 between individuals on whom the drug was evaluated to have an anti-aging effect or
751 not.

752

753

754

755

756

757

758

759

760

761

762

763

764

765


766

767

768


769

770 **Figure S1**




771

772 **Figure S2**




773

774 **Figure S3**




775

776 **Figure S4**



777

778 **Figure S5**



779

780 **Supplement table legend:**

781 **Supplement table 1. Gene ontologies of eight aging trajectories;**

782 **Supplement table 2. List of linear ARGs;**

783 **Supplement table 3. Gene ontologies of linear ARGs;**

784 **Supplement table 4. Model parameter and performance metrics of autogluon;**

785 **Supplement table 5. Feature importance of the ensemble model inferred by**

786 **autogluon;**

787 **Supplement table 6. Parameter grid search result for the elastic-net model;**

788 **Supplement table 7. List of Wave ARGs;**

789 **Supplement table 8. Gene ontologies of linear and wave ARGs in comparison;**

790 **Supplement table 9. Gene ontologies of wave ARGs in quick aging group.**